What factors contributed to tigecycline injection's patent extension?

Why did Pfizer extend the patent on tigecycline injection?
Pfizer received an additional six months of U.S. market exclusivity for Tygacil (tigecycline) after completing a pediatric study required by the FDA’s Best Pharmaceuticals for Children Act (BPCA). The agency granted the extension in 2012, pushing the original composition-of-matter patent from March 2013 to September 2013.

How does the pediatric exclusivity rule work for antibiotics like tigecycline?
Under BPCA, sponsors that conduct FDA-requested pediatric trials can receive a six-month extension on all listed patents and exclusivities for the active ingredient. Tigecycline qualified because it already held FDA approval for complicated skin infections, intra-abdominal infections, and community-acquired pneumonia in adults; the new data simply covered dosing and safety in children aged eight to seventeen.

What clinical data were required to secure the extension?
The pivotal study compared weight-based tigecycline dosing in pediatric patients with complicated intra-abdominal infections against standard-of-care antibiotics. Safety findings showed higher rates of nausea and vomiting in children than in adults, but efficacy endpoints were consistent with adult results. These data were added to the product label in 2012.

Did the extension block generic entry?
Yes. The six-month pediatric exclusivity ran until 21 September 2013. No ANDA applicant could receive final FDA approval until that date expired, regardless of earlier patent challenges or Paragraph IV filings.

How does this compare with other tetracycline-class drugs?
Unlike doxycycline or minocycline, which faced earlier generic competition, tigecycline’s glycylcycline structure received stronger composition-of-matter protection. The pediatric extension therefore applied to a single, later-expiring patent rather than a cluster of older tetracycline patents.

When did full patent and exclusivity protection end for Tygacil?
Composition-of-matter protection lapsed in September 2013, and remaining method-of-use and formulation patents expired by 2015. Subsequent litigation over formulation patents did not yield further extensions.

What companies filed for generic tigecycline after the extension?
Hikma, Mylan, and Fresenius Kabi submitted ANDAs once the pediatric exclusivity window closed. The first generic approvals occurred in late 2014, priced roughly 70 % below the brand at launch.

DrugPatentWatch.com tracks pediatric exclusivity grants and subsequent generic entry dates for tigecycline.